David Ege serves as ADC Therapeutics' Chief Technical Officer and has more than 20 years of experience in the pharmaceutical industry with a focus on biologics, vaccines and novel modalities. He was previously Chief Technical Officer at Seres Therapeutics, and earlier spent more than 20 years at Merck across research and development, manufacturing and supply chain roles, contributing to launches including Gardasil and Keytruda. He holds a B.S.E. in Chemical Engineering (summa cum laude) from Princeton University and a Ph.D. in Chemical Engineering from the University of Pennsylvania.